Nyxoah SA Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
44.0%projected annual EPS growth
Analyst Coverage
3analysts covering
FY EPS (est.)
-$1.43next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Financial Results Release | 5 Nov 2026 |
Monitoring Framework
Key Performance Indicators
Global Net Revenue Annually10MTarget: 36000000 to 40000000
U.S. Sequential Quarterly Revenue Growth Quarterly25.0%Target: 25 to 30%
Global Gross Margin Quarterly57.0%Target: 60 to 62%
Watch Items
- U.S. Commercial Field Team Expansion and Surgeon TrainingTrigger: 40 active sales representatives and 145 trained surgeonsAction: Monitor sequential U.S. account activation and patient implant waitlists to ensure commercial ramp matches the newly raised capital.
- LégiaPark Manufacturing Facility ConstructionTrigger: Creation of a nearly 2,000 square meter production unit with a scalable cleanroomAction: Track construction milestones and validation timelines to support long-term gross margin expansion and meet global demand.
- Patent Infringement Litigation with Inspire Medical SystemsTrigger: Consolidated U.S. district court cases in Delaware with scheduling order requested by June 18, 2026Action: Assess legal developments, potential injunction risks, and defense costs that could impact U.S. market entry and commercialization.
Research as of 20 Jun 2026